system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: OBJECTIVE, METHODS, RESULTS. Meshes: Adult, Aged, Amylases, Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors, Female, Glycated Hemoglobin A, Humans, Hypoglycemic Agents, Lipase, Male, Middle Aged, Pancreatitis, Pyrazines, Retrospective Studies, Risk Assessment, Sitagliptin Phosphate, Triazoles.
user
Does treatment with DPP-4 inhibitors increase the chance of pancreatitis in patients with type 2 diabetes? Context: This retrospective analysis was done in type 2 diabetes patients to study whether treatment with either sitagliptin or other Dipeptidyl peptidase-4 (DPP-4) inhibitors increased the risk of pancreatitis. Comparison with patients treated with other Oral Antidiabetic Drugs (OADs) was done. Asian Indian type 2 diabetic subjects (duration > or = 5 years) treated with sitagliptin or other DPP-4 inhibitors (n = 957) were selected from the clinic records. Control group included patients treated with other hypoglycaemic agents and had serum lipase and/or amylase estimated (n = 718). HbA1c and serum levels of lipase and/or amylase were measured. For lipase, values > or = 90 IU/l and for amylase, values > or = 150 IU/l were considered abnormal. Percentages with elevated lipase values were similar among patients on sitagliptin or other gliptins and control subjects. Similar percentages of patients using DPP-4 inhibitors (6.9%) or other hypoglycaemic agents (8.2%) had elevated levels of lipase. Abnormal amylase values were more common among the control subjects vs those using DPP-4 inhibitors.
assistant
Present analysis suggests that use of DPP-4 inhibitors is safe in patients who do not have contraindications for its use. Final Decision: no